Biomarker Discovery Pipeline

Multi-Omics Biomarker Discovery. From Molecules to Markers

Six modular discovery pipelines: cfDNA methylation, metabolomics, proteomics, phosphoproteomics, miRNA, and lipidomics, unified by a computational integration engine that transforms individual hits into validated biomarker panels.

Single-omics discovery misses the full picture.

Most biomarker programs interrogate one molecular layer at a time, and most discovery candidates fail validation. The problem isn't the biology. It's the approach.

Single-Omics Blind Spots

A protein biomarker without metabolomic context, or a methylation hit without proteomic validation, captures one dimension of a multi-dimensional disease. Single-layer discovery misses signatures that only emerge at the intersection of molecular levels.

High False-Discovery Rates

Without cross-omics validation, discovery programs generate candidate lists full of statistical artifacts. When a methylation change, a protein change, and a metabolite change all point to the same pathway, that convergence is your signal.

Discovery-Validation Disconnect

Discovery at one CRO. Validation at another. Different platforms, different sample handling, different statistical frameworks. By the time candidates reach validation, half the signal is lost to technical variance.

Modular Pipelines, Integrated Discovery

Choose the discovery pipelines that match your biology. We handle the integration, from differential profiling through multi-omics computational fusion into actionable panels.

1

Choose Your Pipelines

Select from 6 modular omics discovery pipelines

Start with one or combine for multi-dimensional profiling

2

Differential Profiling

Condition vs. control cohorts, rigorous statistics

Systematic comparison identifies condition-specific signatures

3

Multi-Omics Integration

Computational fusion of cross-omics signals

Individual hits become validated, actionable biomarker panels

Six Discovery Pipelines

Each pipeline is a complete discovery workflow, from sample processing through statistical analysis and candidate selection. Engage one or combine for multi-omics coverage.

1

cfDNA Methylation Profiling

Epigenetic markers from cell-free DNA in circulation

Bisulfite sequencing (WGBS/RRBS)Methylation arraysTargeted panels
Sample: Plasma (EDTA)Bisulfite PCR
2

Untargeted Metabolomics

Small molecule signatures via high-resolution mass spectrometry

Orbitrap LC-MS/MSDIA acquisitionDual-polarity ESI
Sample: Serum or PlasmaTargeted MRM/SRM
3

Differential Proteomics

Protein abundance changes in circulation

TMT multiplexingLabel-free quantificationHigh-abundance depletion
Sample: Serum or PlasmaELISA / Luminex
4

Phosphoproteomics

Signaling pathway activity through phosphorylation profiling

TiO2/IMAC enrichmentKinase activity inferencePathway mapping
Sample: Serum/Plasma or TissuePhospho-specific ELISA
5

Circulating miRNA Profiling

Stable RNA biomarkers from blood, tissue-specific and disease-responsive

Small RNA-seqNanoString nCounterUMI-based libraries
Sample: Serum or PlasmaRT-qPCR
6

Lipidomics

Lipid species alterations across glycerophospholipids, sphingolipids, and more

Lipid-optimized LC-MS/MSClass-specific quantificationEicosanoid panels
Sample: Serum or PlasmaTargeted MRM

Multi-Omics Integration

The computational layer that transforms individual omics results into unified, systems-level biomarker panels. This is where NexysBio's offering transcends what single-omics CROs can deliver.

Unsupervised Discovery

Multi-Omics Factor Analysis (MOFA+) and Similarity Network Fusion identify latent biological processes driving variation across omics layers, revealing disease subtypes invisible to single-omics analysis.

MOFA+Network FusionJoint NMF

Supervised Panel Selection

Multi-omics machine learning with group-aware regularization selects minimal biomarker panels with cross-omics features. Nested cross-validation ensures performance estimates are unbiased.

Random ForestGroup LASSONested CV

Pathway Integration

Differential molecules from all layers mapped onto KEGG and Reactome pathways. Consensus pathways perturbed across methylation, protein, and metabolite levels provide biologically grounded biomarker rationale.

KEGG/ReactomeMulti-layer OverlayConsensus Scoring

From Individual Hits to Actionable Panels

This is where a methylation marker, a circulating protein, and a lipid species converge into a multi-analyte panel with diagnostic power no single molecule can achieve alone.

Disease Applications

Our discovery platform is condition-agnostic. The same modular pipeline architecture applies to any disease area requiring molecular biomarkers.

Oncology

Early detection panels, minimal residual disease monitoring, treatment response biomarkers

Infectious Disease

Host-response signatures, pathogen-specific metabolic fingerprints, immune correlates

Metabolic Disorders

Insulin resistance profiles, lipid metabolism dysregulation, metabolic syndrome panels

Cardiovascular

Atherosclerosis risk markers, cardiac injury biomarkers, endothelial dysfunction signatures

Neurological

Blood-brain barrier leakage markers, neuroinflammation profiles, neurodegeneration signatures

Autoimmune

Autoantibody panels, inflammatory mediator profiles, disease activity monitoring

Engagement Models

Start with a single pipeline or go end-to-end. Our modular architecture lets you scope the engagement to match your biology, your timeline, and your budget.

Discovery Models

Choose the scope that matches your program stage

  • Single Module: focused discovery in one omics layer with full statistical analysis
  • Multi-Module: two or more pipelines for cross-omics coverage and validation
  • Full Integrated: all six pipelines with multi-omics computational integration
  • Discovery + Validation: end-to-end from untargeted profiling through targeted confirmation

Validation Pathways

How discovery candidates get confirmed

  • Bisulfite PCR: targeted methylation validation at specific CpG loci
  • ELISA / Luminex: protein biomarker quantification in independent cohorts
  • Targeted MRM: mass spectrometry validation of metabolite and lipid candidates
  • RT-qPCR: quantitative validation of miRNA biomarker candidates

Integrated Services

Your biomarker program connects directly to the broader NexysBio platform. Same team, same context, zero transfer delays.

Active

Nano-Drug Formulation

Nanoparticle-based diagnostic delivery. Functionalized particles for biosensor applications and targeted biomarker sampling.

View service
Active

Antibody Engineering

Generate monoclonal antibodies against your discovered protein biomarkers for ELISA development, diagnostic applications, or therapeutic targeting.

View service
Active

Vaccine Antigen Discovery

Immune biomarker profiling feeds directly into vaccine programs, including host response signatures and correlates of protection.

View service
Active

Enzyme & Protein Engineering

Engineered enzymes for diagnostic assay development and signal amplification: custom HRP variants, reporter fusions, and optimized detection reagents.

View service
Active

Bio-Digital Solutions

Custom software built by scientists who understand your workflows, from data dashboards to regulatory-compliant systems.

View service
Coming Soon

Cell-Based Assay Services

Functional validation of biomarker candidates in cell-based systems: reporter assays, stimulation panels, and mechanistic confirmation.

Ready to discover your biomarkers?

Let's design your multi-omics discovery program, from pipeline selection through integrated biomarker panel delivery. We'll scope the right combination of discovery modules for your condition and timeline.

Or email us directly at info@nexysbio.com